847 Optimal dose selection of ADG126 (a masked anti-CTLA-4 SAFEbody®) with significantly widened therapeutic index compared to ipilimumab in combination with anti-PD-1 antibodies informed by QSP modeling

• Xin Wang,
• Yan Li,
• Meng Sun,
• Jiping Zha,
• Songmao Zheng,
• Guizhong Liu,
• Peter Luo,
• John J Skinner,
• Kristine She,
• Jiangchun Xu,
• Felix Du

Affiliations

Xin Wang

2Adagene Inc., Suzhou, China

Yan Li

Department of Dermatovenereology, Tianjin Medical University General Hospital/ Tianjin Institute of Sexually Transmitted Disease, Tianjin, China

Meng Sun

Karolinska Institutet and Karolinska University Hospital, Department of Medicine, Solna, Stockholm, Sweden

Jiping Zha

3Adagene, Inc., San Diego, CA, USA

Songmao Zheng

1Adagene Inc, Ambler, PA, USA

Guizhong Liu

3Adagene, Inc., San Diego, CA, USA

Peter Luo

3Adagene, Inc., San Diego, CA, USA

John J Skinner

2Adagene Inc., Suzhou, China

Kristine She

3Adagene, Inc., San Diego, CA, USA

Jiangchun Xu

3Adagene, Inc., San Diego, CA, USA

Felix Du

2Adagene Inc., Suzhou, China